Bausch + Lomb Co. (NYSE:BLCO) Shares Bought by Renaissance Capital LLC

Renaissance Capital LLC grew its stake in shares of Bausch + Lomb Co. (NYSE:BLCO) by 116.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 94,182 shares of the company’s stock after buying an additional 50,622 shares during the period. Bausch + Lomb accounts for approximately 1.1% of Renaissance Capital LLC’s holdings, making the stock its 23rd biggest holding. Renaissance Capital LLC’s holdings in Bausch + Lomb were worth $1,701,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Barclays PLC acquired a new stake in shares of Bausch + Lomb in the third quarter worth $5,797,000. Quadrature Capital Ltd purchased a new stake in Bausch + Lomb during the 3rd quarter worth $526,000. River Road Asset Management LLC increased its holdings in Bausch + Lomb by 4.4% in the 3rd quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock valued at $38,974,000 after purchasing an additional 85,987 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Bausch + Lomb during the third quarter worth about $957,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Bausch + Lomb in the second quarter worth about $580,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on BLCO. Wells Fargo & Company dropped their target price on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Thursday, January 16th. Bank of America reiterated an “underperform” rating and set a $18.00 price objective on shares of Bausch + Lomb in a research note on Thursday, December 12th. Morgan Stanley downgraded shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price for the company. in a research note on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Bausch + Lomb in a research note on Thursday, December 12th. Finally, Evercore ISI raised shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $19.00 to $25.00 in a research report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $20.25.

Bausch + Lomb Trading Up 0.5 %

NYSE:BLCO opened at $17.45 on Tuesday. The company has a market cap of $6.15 billion, a PE ratio of -16.61, a P/E/G ratio of 2.30 and a beta of 0.46. The business’s 50 day moving average is $18.25 and its two-hundred day moving average is $18.16. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. Bausch + Lomb Co. has a 52 week low of $13.16 and a 52 week high of $21.69.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.